Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided awareness of Zepbound ... is actually not very high," CEO David Ricks said on an earnings call Wednesday morning.
FDA approves a new weight loss drug, Zepbound from Eli Lilly
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
FDA adds new warning to weight loss drugs including Wegovy
The U.S. Food and Drug Administration has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents into their lungs while under anesthesia.
Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss?
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. Whether you have type 2 diabetes or obesity, you may have heard about medications like Ozempic® that can help manage blood sugar levels and weight.
FDA adds new warning to popular weight loss drugs
The Food and Drug Administration has updated labels for popular weight loss drugs like Ozempic and Wegovy.
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Futurism9d
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro
with Zepbound and diabetes drug Mounjaro — the active ingredient in both is tirzepatide, a GLP-1 receptor agonist — missing Wall Street estimates by almost $900 million in sales. Eli Lilly ...
Eli Lilly Misses Quarterly Profit Estimates; Shares Tumble
(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...
STAT12d
Eli Lilly hits rare stumble, as sales and earnings disappoint
Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...